References
- Hale, G., Xia, M.-Q., Tighe, H.P., Dyer, M.J.S. and Waldemann, H. (1990) "The CAMPATH-1H antigen (CDw52)", Tissue Antigens 35, 118–127.
- Hale, G. (2001) "The CD52 antigen and development of the CAMPATH antibodies", Cytotherapy 3, 137–143.
- Riechmann, L., Clark, M., Waldmann, H. and Winter, G. (1988) "Reshaping human antibodies for therapy", Nature 332, 323–327.
- Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., Dyer, M.J.S. and Catovsky, D. (1998) "Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to CAMPATH-1H", Leukemia Research 22, 185–191.
- Dyer, M.J.S. (1999) "The role of CAMPATH-1H antibodies in the treatment of lymphoid malignancies", Seminars in Oncology 26\(Suppl. 14), 52–57.
- Contouriotis, A., Moore, T.B. and Sakamoto, K.M. (2002) "Cell surface antigen and molecular targeting in the treatment of hematologic malignancies", Stem Cells 20, 215–229.
- Bennett, J.M., Catovsky, D., Daniel, M-T., Flandrin, G., Galton, D.A.G., Granlnick, H.R. and Sultan, C. (1989) "Proposal for the classification of chronic (mature) B and T lymphoid leukaemias", Journal of Clinical Pathology 42, 567–584.
- Harris, N.L., Jaffe, ES., Stein, H., Banks, P.M., Chan, J.K.C., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B., Gatter, K.C., Grogan, T.M., Isaacson, P.G., Knowles, D.M., Mason, D.Y., Muller-Hermelink, H.-K., Pileri, S.A., Piris, Ralfkiaer, E. and Warnke, R.A. (1994) "A revised European—American classification of lymphoid neoplasms: a proposal from the international lymphoma study group", Blood 84, 1361–1392.
- D'Arena, G., Keating, M.J. and Carotenuto, M. (2000) "Chronic lymphoproliferative disorders: an integrated point of view for the differential diagnosis", Leukemia and Lymphoma 36, 225–237.
- Iyer, S.B., Bishop, J.E., Abrams, B., Maino, V.C., Ward, AL, Christian, T.P. and Davis, K.A. (1997) QuantiBRITE: A New Standard for Fluorescence Quantitation (White Paper) (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA).
- Davis, K.A. and Bishop, J.E. (1997). "Determination of fluorescent molecules on calibration beads for flow cytometry", U.S. Patent, No. 5, 620, 842.
- D'Arena, G., Musto, P., Cascavilla, N., Dell' Olio, M., Di Renzo, N. and Carotenuto, M. (2000) "Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoprolifera-tive disorders", American Journal of Hematology 64, 275–281.
- D'Arena, G., Dell'Olio, M., Musto, P., Cascavilla, N., Perla, G., Savino, L. and Greco, M.M. (2001) "Morphologically typical and atypical B-cell chronic lymphocytic leukemias display a different pattern of surface antigenic density", Leukemia and Lymphoma 42, 649–654.
- Henderson, L.O., Marti, G.E., Gaigalas, A., Hannon, W.H. and Vogt, R.F. (1998) "Terminology and nomenclature for standardi-zation in quantitative fluorescence cytometry", Cytometry 33, 97–105.
- Dyer, M.J.D. (1999) "The role of Campath-1 antibodies in the treatment of lymphoid malignancies", Seminars in Oncology 26, 52–57.
- Birhiray, R.E., Shaw, G., Guldan, S., Rudolf, D., Delmastro, D., Santabarbara, P. and Brettman, L. (2002) "Phenotypic transforma-tion of CD52r's to CD52'eg leukemic T cells as a mechanism for resistance to CAMPATH-1H", Leukemia 16, 861–864.
- Golay, J., Lazzari, M., Facchinetti, V, Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A. and Introna, M. (2001) "CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59", Blood 98, 3383–3389.
- Perz, J., Topaly, J., Fruehauf, S., Hensel, M. and Ho, A.D. (2002) "Level of CD20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia", Leukemia and Lymphoma 43, 149–151.